Association with Vitamin D

Manjula Nandakumar,Priya Das,Thozhukat Sathyapalan,Alexandra E. Butler,Stephen L. Atkin
DOI: https://doi.org/10.3390/ijms25126330
IF: 5.6
2024-06-08
International Journal of Molecular Sciences
Abstract:Vitamin D is proposed to have a protective effect against cardiovascular disease, though the mechanism is unclear. Vitamin D deficiency is common in polycystic ovary syndrome (PCOS), where it is strongly related to obesity, insulin resistance (IR) and risk of cardiovascular disease. To determine if the inherent pathophysiology of PCOS or vitamin D levels are linked to dysregulation of cardiovascular risk proteins (CVRPs), a study in non-obese women with PCOS and without IR was undertaken. Our hypothesis was that the levels of vitamin D3 and its active metabolite would be associated with CVRPs comparably in women with and without PCOS. In women with PCOS (n = 29) and controls (n = 29), 54 CVRPs were determined by Slow Off-rate Modified Aptamer (SOMA)-scan plasma protein measurement and correlated to 25-hydroxyvitamin D3 (25(OH)D3) and the active 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) measured by gold standard isotope-dilution liquid chromatography tandem mass spectrometry. Women with PCOS had comparable IR and systemic inflammation (normal C-reactive protein) to control women, though had higher free androgen index and anti-Mullerian hormone levels. 25(OH)D3 and 1,25(OH)2D3 levels did not differ between groups. Nine CVRPs were higher in PCOS (p < 0.05) (Galectin-9, Brother of CDO, C-motif chemokine 3, Interleukin-18 receptor-1, Thrombopoietin, Interleukin-1 receptor antagonist protein, Programmed cell death 1 ligand-2, Low-affinity immunoglobulin gamma Fc-region receptor II-b and human growth hormone), whilst 45 CVRPs did not differ. 25(OH)D3 correlated with five CVRPs in PCOS and one in controls (p < 0.05). Despite the women with PCOS not exhibiting overt systemic inflammation, 9 of 54 CVRPs were elevated, all relating to inflammation, and 5 of these correlated with 25(OH)D3, suggesting an ongoing underlying inflammatory process in PCOS even in the absence of obesity/IR.
biochemistry & molecular biology,chemistry, multidisciplinary
What problem does this paper attempt to address?
### What problem does the paper attempt to solve? The paper aims to explore whether the inherent pathophysiology of Polycystic Ovary Syndrome (PCOS) or vitamin D levels are related to changes in cardiovascular risk proteins (CVRPs). The study hypothesizes that in non-obese and insulin resistance (IR)-free PCOS patients, the levels of vitamin D3 (25(OH)D3) and its active metabolite 1,25(OH)2D3 will be associated with CVRPs, but the levels of CVRPs will not differ between non-obese PCOS patients and the control group. The study subjects included 29 non-obese PCOS patients and 29 matched non-PCOS controls. The results showed that 9 CVRPs were significantly elevated in the PCOS group, and these changes were related to inflammation and immune response. Although vitamin D levels were comparable between the two groups, four CVRPs were found to be negatively correlated with 25(OH)D3 and one positively correlated in the PCOS group; whereas in the control group, only one CVRP was related to 25(OH)D3. These results suggest that changes in CVRPs may be an inherent feature of PCOS and may be related to early inflammation and changes in vitamin D metabolites. Specifically, the study found the following CVRPs to be significantly elevated in the PCOS group: - Galectin-9 (LEG9) - Brother of CDO (BOC) - C-motif chemokine 3 (MIP-1α) - Interleukin-18 receptor 1 (IL-18R1) - Thrombopoietin (TPO) - Interleukin-1 receptor antagonist protein (IL-1Ra) - Programmed cell death 1 ligand 2 (PD-L2) - Low-affinity immunoglobulin gamma Fc region receptor II-b (FCG2B) - Human growth hormone (HGH) These changes are related to inflammation and immune response, further supporting the presence of chronic low-level inflammation in PCOS, even in the absence of overweight or obesity. Therefore, these results suggest the presence of early inflammatory markers in non-obese PCOS patients, and these markers may become potential biomarkers.